Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Pediatr Blood Cancer. 2021 Apr 12;68(8):e29031. doi: 10.1002/pbc.29031

TABLE 3:

Best response for patients with measurable disease.




Temozolomide + Irinotecan
Temozolomide + Irinotecan - Bevacizumab
Characteristics
Categories
N (%)
N (%)
Best Response Complete response 0 (0.0) 8 (17.4)
 Non-responder 2 (4.2) 1 (2.2)
 Progressive disease 16 (33.3) 6 (13.0)
 Partial response 16 (33.3) 14 (30.4)
 Stable disease 14 (29.2) 17 (37.0)